[{"Assets_0_FY_USD":261515000.0,"CommonStockSharesOutstanding_0_FY_shares":129502000.0,"EarningsPerShareBasic_1_FY_USD":0.03,"EarningsPerShareDiluted_1_FY_USD":0.03,"NetCashProvidedByUsedInOperatingActivities_4_FY_USD":-50383000.0,"NetIncomeLoss_1_FY_USD":4318000.0,"NetIncomeLoss_4_FY_USD":-103023000.0,"StockholdersEquity_0_FY_USD":-32481000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_FY_shares":129248000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_FY_shares":127197000.0,"Ticker":"HALO","CIK":"1159036","name":"HALOZYME THERAPEUTICS INC","OfficialName":"Halozyme Therapeutics Inc. Common Stock","form":"10-K","period":"20161231","fy":"2016.0","fp":"FY","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"5856719603.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20170228"}]